HOPO 14-1 explained

Drug Name:	3,4,3-LI(1,2-HOPO)
Legal Status:	Investigational
Cas Number:	110874-36-7
Chembl:	264485
Chemspiderid:	117108
Pubchem:	132648
Unii:	R6SML525FN
Iupac Name:	N,N′-1,4-Butanediylbis[''N''-[3-[[(1,6-dihydro-1-hydroxy-6-oxo-2-pyridinyl)carbonyl]amino]propyl]-1,6-dihydro-1-hydroxy-6-oxo-2-pyridinecarboxamide]
C:	34
H:	38
N:	8
O:	12
Smiles:	O=C1C=CC=C(C(=O)NCCCN(C(=O)C2=CC=CC(=O)N2O)CCCCN(C(=O)C3=CC=CC(=O)N3O)CCCNC(=O)C4=CC=CC(=O)N4O)N1O
Stdinchi:	1S/C34H38N8O12/c43-27-13-3-9-23(39(27)51)31(47)35-17-7-21-37(33(49)25-11-5-15-29(45)41(25)53)19-1-2-20-38(34(50)26-12-6-16-30(46)42(26)54)22-8-18-36-32(48)24-10-4-14-28(44)40(24)52/h3-6,9-16,51-54H,1-2,7-8,17-22H2,(H,35,47)(H,36,48)
Stdinchikey:	KUWKQASGHNTJAT-UHFFFAOYSA-N

HOPO 14-1 is an investigational drug product for removing radioactive contaminants from the body. It is an oral capsule designed to act as a defence against radioactive threats such as nuclear power plant accidents or dirty bomb attacks.^{[1] [2]} The active ingredient is the hydroxypyridinone ligand 3,4,3-LI(1,2-HOPO), which is a powerful chelating agent.^{[1] [3]} HOPO 14-1 works by selectively binding to heavy metals in the body and forming a complex that the body can naturally excrete.^[4] The drug is also being studied as a treatment for other forms of heavy metal toxicity, including lead poisoning and exposure to gadolinium from MRI contrast agents.^{[5] [6] [7] [8]} HOPO 14-1 was developed at Lawrence Berkeley National Laboratory by actinide chemist Rebecca Abergel. Abergel and former postdoc Julian Avery Rees co-founded HOPO Therapeutics, a company commercializing HOPO 14-1 and other treatments for heavy metal poisoning.

See also

• Diethylenetriamine pentaacetate

Notes and References

1. Web site: 2023-05-15 . First-in-human trial of oral drug to remove radioactive contamination begins . 2023-05-16 . National Institutes of Health (NIH) . EN.
2. News: Roberts M . 2023-05-16 . Dirty-bomb antidote: Drug trial begins in US . en-GB . BBC News . 2023-05-16.
3. Wang Q, Liu Z, Song YF, Chai Z, Wang D . Chelation Behaviors of 3,4,3-LI(1,2-HOPO) with Lanthanides and Actinides Implicated by Molecular Dynamics Simulations . Inorganic Chemistry . 62 . 10 . 4304–4313 . March 2023 . 36847745 . 10.1021/acs.inorgchem.2c04460 . 257218983 .
4. Abergel RJ, Durbin PW, Kullgren B, Ebbe SN, Xu J, Chang PY, Bunin DI, Blakely EA, Bjornstad KA, Rosen CJ, Shuh DK, Raymond KN . 6 . Biomimetic actinide chelators: an update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO) . Health Physics . 99 . 3 . 401–407 . September 2010 . 20699704 . 2921233 . 10.1097/HP.0b013e3181c21273 .
5. Rees JA, Deblonde GJ, An DD, Ansoborlo C, Gauny SS, Abergel RJ . Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents . Scientific Reports . 8 . 1 . 4419 . March 2018 . 29535330 . 5849765 . 10.1038/s41598-018-22511-6 . 2018NatSR...8.4419R .
6. Web site: 2019-09-12 . This Anti-Nuclear-Contimation Pill Could Also Help MRI Patients . 2023-05-29 . Lawrence Berkeley National Laboratory (Berkeley Lab) . EN.
7. Web site: 2021-10-21 . Rebecca Abergel - Bakar Fellows Program . 2023-05-29 . Bakar Fellows Program, UC Berkeley . EN.
8. Web site: 2023-05-29 . HOPO Therapeutics . 2023-05-29 . HOPO Therapeutics, Inc. . EN.